Acquired tamoxifen resistance in human breast cancer - Potential mechanisms and clinical implications

Anti-Cancer Drugs

Volumn 8, Issue 10, 1997, Pages 911-930

  Johnston, Stephen R D ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Acquired resistance; Breast cancer; Estrogen receptor; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; DROLOXIFENE; DRUG METABOLITE; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; IDOXIFENE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PROTEIN BCL 2; RALOXIFENE; TAMOXIFEN; TOREMIFENE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CELL DEATH; CELL PROLIFERATION; CLINICAL TRIAL; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESISTANCE; DRUG TOLERANCE; FEMALE; HUMAN; PRIORITY JOURNAL; REVIEW; RNA SPLICING;

EID: 0031471007     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199711000-00002     Document Type: Review

References (165)

1. Mouridsen HT, Ellemann K, Mattsson W, Palshof T, Daehnfeldt JL, Rose C. Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women. Cancer Treat Rep 1979; 63: 171-5.
2. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992; 39: 1-15, 71-85.
3. Powles TJ, Tillyer CR, Jones AL, et al. Prevention of breast cancer with tamoxifen - an update on the Royal Marsden Hospital pilot programme. Eur J Cancer 1990; 26: 680-4.
4. Howell A, Mackintosh J, Jones M, RedfordJ, Wagstaff J, Sellwood R. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 1988; 24: 1567-72.
5. Kuss JT, Muss HH, Hoen H, Case LD. Tamoxifen as initial endocrine therapy for metastatic breast cancer: long term follow-up of two Piedmont Oncology Association (POA) trials. Breast Cancer Res Treat 1997; 42: 265-74.
6. Muss HB, Smith LR, Cooper MR. Tamoxifen rechallenge; response to tamoxifen following relapse after adjuvant chemo-hormonal therapy for breast cancer. J Clin Oncol 1987; 5: 1556-8.
7. Dowsett M, Harris AL, Smith IE, Jeffcoate SL. Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy. J Clin Endocrol Metab 1984; 58: 99-104.
8. Ravdin PM, Fritz NF, Tormey DC, Jordan VC. Endocrine status of pre-menopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res 1988; 48: 1026-9.
9. Iino Y, Wolf DM, Langhan-Fahey SM, et al. Reversible control of oestradiol-stimulated growth of MCF-7 tumours by tamoxifen in the athymic mouse. Br J Cancer 1991; 64: 1019-24.
10. Horwitz KB, Costlow ME, McGuire WL. A human breast cancer cell line with estrogen, androgen, progesterone and glucocortiocoid receptors. Steroids 1975; 26: 785-95.
11. Lippman ME, Bolan G, Huff K. The effects of estrogens and antiestrogens on hormone responsive human breast cancer in long-term tissue culture. Cancer Res 1976; 36: 4595-601.
12. Coezy E, Borgna J-L, Rochefort H. Tamoxifen and metabolites in MCF-7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 1982; 42: 317-23.
13. 1 phase. Cancer Res 1983; 43: 3583-5.
14. 1 phase of the cell cycle. Eur J Cancer Clin Oncol 1983; 19: 615-21.
15. Westley BR, May FEB. In vitro development of tamoxifen resistance. Endocr Rel Cancer 1995; 2: 37-44.
16. Osborne CK, Hobbs K, Clark GM. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 1985; 45: 584-90.
17. Gottardis MM, Robinson SP, Jordan VC. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 1988; 30: 311-4.
18. Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antioestrogen administration. Cancer Res 1988; 48: 5183-7.
19. Gottardis MM, Jiang S-Y, Jeng M-H, Jordan VC. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 1989; 49: 4090-3.
20. Howell A, Dodwell DJ, Laidlaw I, Anderson H, Anderson E. Tamoxifen as an agonist for metastatic breast cancer. In: Goldhirsch A, ed. Endocrine therapy of breast cancer. New York: Springer-Verlag 1990: 49-58.
21. Osborne CK, Coronado E, Allred DC, Wiche V, DeGregorio M. Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerisation of trans-4-hydroxytamoxifen. J Natl Cancer Inst 1991; 83: 1477-82.
22. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995; 87: 746-50.
23. Chander SK, McCague R, Luqmani Y, et al. Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antioestrogen tamoxifen for the treatment of breast cancer. Cancer Res 1991; 51: 5851-8.
24. Coombes RC, Haynes BP, Dowsett M, et al. Idoxifene: report of a phase I study in patients with metastatic breast cancer. Cancer Res 1995; 55: 1070-4.
25. Johnston SRD, Smith IE, Haynes BP, Jarman M, Dowsett M. The effects of a novel antioestrogen Idoxifene on the growth of tamoxifen-sensitive and resistant MCF-7 xenografts in athymic mice. Br J Cancer 1997; 75: 804-9.
26. Legault-Poisson S, Jolivet J, Poisson R, Beretta-Piccoli M, Band PR. Tamoxifen-induced tumor stimulation and withdrawal response. Cancer Treat Rep 1979; 63: 1839-41.
27. Canney PA, Griffiths T, Latief TN. Clinical significance of tamoxifen withdrawal response. Lancet 1987; i: 36.
28. Howell A, Dodwell DJ, Anderson H, Radford J. Response after withdrawal of tamoxifen and progestins in advanced breast cancer. Ann Oncol 1992; 3: 611-7.
29. Sawka CA, Pritchard KI, Paterson AHG, et al. Role and mechanisms of action of tamoxifen in pre-menopausal women with metastatic breast cancer. Cancer Res 1986; 46: 3152-6.
30. Hoogstraten B, Gad-el-Mawla N, Maloney TR, Flethcher WS. Combined modality therapy for first recurrence of breast cancer. Cancer 1984; 54: 2248-56.
31. Ruenitz PC, Bagley JR, Pape CW. Some chemical and biochemical aspects of liver microsomal metabolism of tamoxifen. Drug Metab Dispos 1984; 12: 478-83.
32. Jacolot F, Simon I, Dreano Y, Beaune P, Riche C, Berthou F. Identification of the cytochrome p450 IIIa family as enzymes involved in the N-demethylation of tamoxifen in human liver micrososmes. Biochem Pharmacol 1991; 41: 1911-9.
33. Adam HK, Douglas EJ, Kemp JV. The metabolism of tamoxifen in humans. Biochem Pharmacol 1979; 27: 145-7.
34. Fromson JM, Pearson S, Bramah S. The metabolism of tamoxifen (ICI 46,474). Part 1. In laboratory animals. Xenobiotica 1973; 693-709.
35. Daniel P, Gaskel SJ, Bishop H, Campbell C, Nicholson RI. Determination of tamoxifen and an hydroxylated metabolite in plasma from patients with advanced breast cancer using gas chromatography-mass spectrometry. J Endocrinol 1979; 83: 401-8.
36. Jordan VC, Collins MM, Rowsby L, Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 1977; 75: 305-16.
37. Lyman SD, Jordan VC. Metabolism of tamoxifen and its uterotrophic activity. Biochem Pharmacol 1985; 34: 2787-94.
38. Katzenellenbogen JA, Carlson KE, Katzenellenbogen BS. Facile geometric isomerisation of phenolic non-steroidal estrogens and antiestrogens: limitations to the interpretation of experiments characterising the activity of individual isomers. J Steroid Biochem 1985; 22: 31-6.
39. Lieberman ME, Jordan VC, Fritsch M, Santos MA, Gorski J. Direct and reversible inhibition of estradiol stimulated prolactin synthesis by antiestrogens in-vitro. J Biol Chem 1983; 258: 4734-40.
40. Osborne CK, Wiebe VJ, McGuire WL, Ciocca DR, DeGregorio MW. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol 1992; 10: 304-10.
41. Wiebe VJ, Osborne CK, McGuire WL, DeGregorio MW. Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. J Clin Oncol 1992; 10: 990-4.
42. McCague R. Halogenated tamoxifens. British Patent Application No. 621908: 1986.
43. Wolf DM, Langhan-Fahey SM, Parker CJ, McCaque R, Jordan VC. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerisable analogues of tamoxifen and metabolites. J Natl Cancer Inst 1993; 85: 806-12.
44. Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling AE. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 1994; 34: 89-95.
45. Daniel P, Gaskell SJ, Bishop H, Campbell C, Robertson RI. Determination of tamoxifen and biologically active metabolites in human breast tumours and plasma. Eur J Cancer Clin Oncol 1981; 17: 1183-9.
46. Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady state treatment. Cancer Res 1991; 51: 4837-44.
47. Lien EA, Wester K, Lonning PE, Solheim E, Ueland PM. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br J Cancer 1991; 63: 641-5.
48. Johnston SRD, Haynes BP, Sacks NPM, et al. Effect of estrogen receptor status and time on the intra-tumoral accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary bresat cancer. Breast Cancer Res Treat 1993; 28: 241-50.
49. Sutherland RL, Murphy LC, Foo MS, Green MD, Whybourne AM, Krozowski ZS. High affinity antiestrogen binding site distinct from the estrogen receptor. Nature 1980; 288: 273-5.
50. Pavlik EJ, Nelson K, Srinivasan S, et al. Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity. Cancer Res 1992; 52: 4106-12.
51. Langhan-Fahey SM, Tormey DC, Jordan VC. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer 1990; 26: 883-8.
52. Johnston SRD, Haynes BP, Smith IE, et al. Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet 1993; 342: 1521-2.
53. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cells mutants. Biochem Biophys 1976; 455: 152-62.
54. Ramu A, Glaubiger D, Fuks Z. Reversal of acquired resistance to daunorubicin in P388 murine leukaemia cells by tamoxifen and other triparanol analoques. Cancer Res 1984; 44: 4392-5.
55. Maenpaa J, Wiebe V, Koester S, et al. Tamoxifen stimulates in vivo growth of drug-resistant estrogen receptor-negative breast cancer. Cancer Chemother Pharmacol 1993; 32: 396-8.
56. Keen JC, Miller EP, Bellamy C, Dixon JM, Miller WR. P-glycoprotein and resistance to tamoxifen. Lancet 1994; 43: 1047-8.
57. Wiebe VJ, DeGregorio MW, Osborne CK. Tamoxifen metabolism and resistance. In: Dickson RB, Lippmann ME, eds. Drug and hormonal resistance in breast cancer. London; Ellis Horwood 1995: 115-31.
58. Clarke RB, Currier S, Kaplan O, et al. Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. J Natl Cancer Inst 1992; 84: 1506-12.
59. Filipits M, Suchomel RW, Dekan G, et al. MRP and MDR1 gene expression in primary breast carcinomas. Clin Cancer Res 1996; 2: 1231-7.
60. Reddel RR, Sutherland RL. Tamoxifen stimulation of human breast cancer cell proliferation in-vitro: a possible model for tamoxifen tumour flare. Eur J Cancer Clin Oncol 1984; 20: 1419-24.
61. DeFriend DJ, Anderson E, Bell J, et al. Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in-vitro. Br J Cancer 1994; 70: 204-11.
62. Horwitz KB, Koseki Y, McGuire WL. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 1978; 103: 1742-51.
63. Graham II ML, Smith JA, Jewett PB, Horwitz KB. Heterogeneity of progesterone receptor content and remodeling by tamoxifen characterize subpopulations of cultured human breast cancer cells: analysis by quantitative dual parameter flow cytometry. Cancer Res 1992; 52: 593-602.
64. Jiang S-Y, Jordan VC. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNA's for estrogen receptor. J Natl Cancer Instit 1992; 84: 580-91.
65. Jiang S-Y, Langhan-Fahey SM, Stella A, McCague R, Jordan VC. Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stablely expressing complementary DNA's for ER. Mol Endocrinol 1992; 6: 2167-74.
66. Jiang S-Y, Parker CJ, Jordan VC. A model to describe how a point mutation of the estrogen receptor alters the structure function relationship of antiestrogens. Breast Cancer Res Treat 1993; 26: 139-48.
67. McDonnell DP, Clemm, T. Hermann, DL. Goldman, ME Pike. JW. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogen. Mol Endocrinol 1995; 9: 659-69.
68. McGuire WL. Hormone receptors; their role in predicting prognosis and response to endocrine therapy. Semin Oncol 1798; 5: 428-33.
69. Osborne CK. Heterogeneity in hormone receptor status in primary and metastatic breast cancer. Semin Oncol 1985; 12: 317-26.
70. Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y. Proliferation, hormonal responsiveness, and estrogen receptor content of human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 1987; 47: 4355-60.
71. Allegra JC, Barlock A, Huff KK, Lippman ME. Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer 1980; 45: 792-4.
72. Hull DF, Clark GM, Osborne CK, Chamness GC, Knight WA, McGuire WL. Multiple estrogen receptor assays in human breast cancer. Cancer Res 1983; 43: 413-6.
73. Taylor RE, Powles TJ, Humphreys J, et al. Effects of endocrine therapy on steroid receptor content of breast cancer. Br J Cancer 1982; 45: 80-5.
74. Encarnacion CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SAW, Osborne CK. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 1993; 26: 237-46.
75. Howell A, De Friend D, Robertson J, Blamey R, Walton P. Response to the pure antioestrogen ICI 182,780 in tamoxifen resistant breast cancer. Lancet 1995; 345: 29-30.
76. Smith IE, Harris AL, Morgan M. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomised cross-over trial. Br Med J 1981; 283: 1432-4.
77. Johnston SRD, Saccani-Jotti G, Smith IE, et al. Changes in ER, PgR, pS2 expression in tamoxifen resistant human breast cancer. Cancer Res 1995; 55: 3331-8.
78. Kuukasjarvi T, Kononen J, Helin H, Holli Isola G. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1997; 14: 258.
79. Holdaway IM, Bowditch JV. Variation in receptor status between primary and metastatic breast cancer. Cancer 1983; 52: 479-85.
80. Kumar V, Chambon P. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 1988; 55: 145-56.
81. Dickson RB, Lippman ME. Control of human breast cancer by oestrogen, growth factors and oncogenes. In: Lippmann ME, Dickson RB, eds. Breast cancer: cellular and molecular biology. Boston: Kluwer Academic Publishers 1988: 119-65.
82. Bates SE, Davidson NE, Valverius EM, et al. Expression of transforming growth factor alpha and mRNA in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol 1988; 2: 543-55.
83. Sluyser M, Mester J. Oncogenes homologous to steroid receptors? Nature 1985; 15: 546.
84. Koh EH, Wildrick DM, Hortobagyi GN, Blick M. Analysis of the estrogen receptor gene structure in human breast cancer. Anticancer Res 1989; 9: 1841-6.
85. Mahfoudi A, Roulet E, Dauvois S, Parker MG, Wahli W. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci USA 1995; 92: 4206-10.
86. Wolf DM, Jordan VC. The estrogen receptor from a tamoxifen stimulated MCF-7 tumour variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat 1994; 31: 129-38.
87. Jordan VC, Catherino WL, Wolf DM. Drug resistance to tamoxifen: mutant estrogen receptors as a potential mechanism of tamoxifen-stimulated growth. Endocrine Rel Cancer 1995; 2: 45-51.
88. Karnick PS, Kulkarni S, Liu X-P, Budd GT, Bukowski RM. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 1994; 54: 349-53.
89. Roodi N, Bailey LR, Kao W-Y, et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst 1995; 87: 446-51.
90. Andersen TI, Wooster R, Laake K, et al. Screening for inherited and somatic estrogen receptor gene (ESR) base mutations. Human Mut 1997; 9: 531-6.
91. Fuqua SAW, Fitzgerald SD, Chamness GC, et al. Variant human breast tumour estrogen receptor with constitutive transcriptional activity. Cancer Res 1991; 51: 105-9.
92. Fuqua SAW, Fitzgerald SD, Allred DC et al. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res 1992; 52: 483-6.
93. Pfeffer U, Fecarotta E, Vidali G. Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and in MCF-7 cells. Cancer Res 1995; 55: 2158-65.
94. Zhang Q-X, Borg A, Fuqua SAW. An exon 5 deletion variant of the estrogen receptor frequently coexpressed with wild-type estrogen receptor in human breast cancer. Cancer Res 1993; 53: 5882-4.
95. Wang Y, Miksicek RJ. Identification of a dominant negative form of the human cstrogen receptor. Mol Endocrinol 1991; 5: 1707-15.
96. McGuire WL, Chamness GC, Fuqua SAW. Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 1991; 5: 1571-7.
97. Miksicek RJ, Lei Y, Wang Y. Exon skipping gives rise to alternatively spliced forms of the estrogen receptor in breast tumor cells. Breast Cancer Res Treat 1993; 26: 163-74.
98. Fuqua SAW, Wolf DM. Molecular aspects of estrogen receptor variants in breast cancer. Breast Cancer Res Treat 1995; 35: 233-41.
99. Rea D, Parker MG. Effects of exon 5 variant of the estrogen receptor in MCF-7 breast cancer cells. Cancer Res 1996; 56: 1556-63.
100. R-1 compared to the parental MCF-7 cell line. Mol Cell Endocrinol 1995; 109: 197-207.
101. Daffada AAI, Johnston SRD, Smith IE, Detre S, King N, Dowsett M. Exon-5 deletion variant estrogen receptor mRNA expression in tamoxifen resistant breast cancer and its association with PgR/pS2 status. Cancer Res 1995; 55: 288-93.
102. van den Burg B., van Selm-Miltenburg AJP, De Laat SW, van Zoelan EJJ. Direct effects of estrogen on c-fos and c-myc protooncogene expression and cellular proliferation in human breast cancer cells. Mol Cell Endocrinol 1989; 64: 223-8.
103. Sutherland RL, Watts CKW, Musgrove EA. Cell cycle control by steroid hormones in breast cancer: implications for endocrine resistance. Endocr Rel Cancer 1995; 2: 87-96.
104. Musgrove EA, Hamilton JA, Lee CSL, Sweeney KJE, Watts CKW, Sutherland RL. Growth factor, steroid and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 1993; 13: 3577-87.
105. Zwijsen RML, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJAM. CDK-independent activation of estrogen receptor by cyclin D1. Cell 1997; 88: 405-15.
106. Michalides R, Hageman P, van Tinteren H, et al. A clinico-pathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 1996; 73: 728-34.
107. Pollack MJ, Constantino C, Polychronakos SA, et al. Effects of tamoxifen on serum insulin-like growth factor levels in stage I breast cancer patients. J Natl Cancer Instit 1990; 82: 1693-7.
108. Gullino AG, Barrera R, Vacca A. Calmodulin antagonism and growth-inhibiting activity of triphenylethylene antioestrogens in MCF-7 human breast cancer cells. Cancer Res 1986; 46: 6274-8.
109. O'Brian CA, Liskamp RM, Solomon DH, Weinstein IB. Triphenylethylenes: a new class of protein kinase C inhibitors. J Natl Cancer Instit 1986; 76: 1243-6.
110. Meyers MO, Alperin-Lea RC, Flattmann GJ, Woltering EA. Tamoxifen inhibits human angiogenesis. Proc Am Ass Cancer Res 1997; 38: A1379.
111. Kute TE, Linville C, Mehta RG, Moon RC. Cell kinetics in normal and neoplastic mammary tissues by flow cytometric analysis. Cytometry 1985; 6: 362-7.
112. Clarke RB, Laidlaw IJ, Jones LJ, Howell A, Anderson E. Effect of tamoxifen on Ki-67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer 1983; 67: 606-11.
113. Dowsett M, Makris A, Ellis P, et al. Oncogene products and other diagnostic markers in human breast cancer patients: treatment effects and their significance. Ann NY Acad Sci 1996; 784: 403-11.
114. Brunner N, Bronzer D, Vindelov LL, et al. Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice. Cancer Res 1989; 49: 1515-20.
115. Sen S, D'Incalci M. Apoptosis. Biochemical events and relevance to cancer chemotherapy. FEBS Lett 1992; 307: 122-7.
116. Perry RR, Kang Y, Greaves B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and independent human breast cancer cells. Ann Surg Oncol 1995; 2: 238-45.
117. Warri AM, Huovinen RL, Laine AM, Martikainen PM, Harkonen PL. Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst 1993; 85: 1412-8.
118. Kyprianou N, English HF, Davidson NE. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 1991; 51: 162-6.
119. Wang TTY, Phang JM. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 1995; 55: 2487-9.
120. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL. Bcl-2 in normal human breast and carcinoma, association with estrogen receptor-positive, epidermal growth factor-negative tumours and in-situ cancer. Br J Cancer 1994; 69: 135-9.
121. Nathan B, Anbazhagan R, Dyer M, Ebbs SR, Jayatilake H, Gusterson BA. Expression of bcl-2 like immunoreactivity in the normal breast and in breast cancer. The Breast 1993; 2: 134-7.
122. Silvestrini R, Verenoni S, Daidone MG, Benini E, Borscchi P. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994; 86: 499-504.
123. Teixeira C, Reed JC Pratt MAC. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995; 55: 3902-7.
124. S sensitizes MCF-7 cells to chemotherapy induced apoptosis. Cancer Res 1995; 55: 2507-10.
125. D, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin Cancer Res 1996; 2: 1215-9.
126. Mainwairing PN, Salter J, Johnston SRD, Ellis PA, Smith IE, Ebbs SR, Dowsett M. Breast Cancer Res Treat 1996; 41: 289.
127. Carpenter G, Stoycheck CM, Preston YA, DeLarco JE. Antibodies to the epidermal growth factor receptor block the biological activities of sarcoma growth factor: Proc Natl Acad Sci USA 1983; 80: 5672-30.
128. Saloman DS, Zweibel JA, Mozeena S, et al. Presence of transforming growth factors in human breast cancer cells. Cancer Res 1984; 44: 4069-77.
129. Zajchowski D, Band V, Pauzie N, Tager A, Stampfer M, Sager R. Expression of growth factors and oncogenes in normal and tumor-derived human mammary epithelial cells. Cancer Res 1988; 48: 7041-7.
130. Yee D, Paik S, Lebovic GS. Analysis of insulin-like growth factor 1 gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol 1989; 3: 509-17.
131. Friess G, Rochefort H, Vignon F. Biochem Biophys Res Commun 1990; 173: 919-26.
132. Lonning PE, Helle SI, Frost VJ, Holly JMP, Hall K. Alterations in plasma IGF-1 cause by hormonal manipulation; of relevance to the mechanism of action and acquired resistance to endocrine treatment in breast cancer. Endocrol Rel Cancer 1995; 2: 127-30.
133. Osborne CK, Ross C, Coronado CB, et al. Secreted growth factors from estrogen-receptor negative human breast cancer do not support growth of estrogen-receptor positive breast cancer in the nude mouse model. Breast Cancer Res Treat 1988; 11: 211-9.
134. Murphy CS, Pink JJ, Jordan VC. Characterization of a receptor-negative, hormone nonresponsive clone derived from a T47D breast cancer cell line kept under estrogenfree conditions. Cancer Res 1990; 50: 7285-92.
135. Knabbe C, Lippman ME, Wakefield LM, et al. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48: 417-28.
136. Colletta AA, Wakefield LM, Howell FV, et al. Antiestrogens induce the secretion of active transforming growth factor-β from human fetal fibroblasts. Br J Cancer 1990; 62: 405-9.
137. King RJB, Wang DY, Daly RJ, Darbre PD. Approaches to studying the role of growth factors in the progression of breast tumours from the steroid sensitive to insensitive state. J Steroid Biochem 1989; 34: 133-8.
138. Thompson AM, Kerr DJ, Steel CM. Transforming growth factor beta-1 is implicated in the failure of tamoxifen therapy in human breast cancer: Br J Cancer 1991; 63: 609-14.
139. Downward J, Yarden Y, Mayers E, et al. Close similarity of epidermal growth factor receptor and v-erb-H oncogene protein sequences. Nature 1984; 307: 521-7.
140. Sainsbury JRC, Farndon JR, Sherbet G, Harris AL. Epidermal growth factor receptors and oestrogen receptors in human breast cancers. Lancet 1985; i: 364-6.
141. Sainsbury JRC, Farndon JR, Needham GK, et al. Epidermal growth factor receptor status as predictor of early recurrence and of death from breast cancer: Lancet 1987; i: 1398-402.
142. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology of EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-9
143. van den Vijer M, van den Bersselaar R, Devilee P, Cornelisse C, Peterse J, Nusse R. Amplification of the neu (c-erb-B2) oncogene in human mammary tumours is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol 1987; 7: 2019-23.
144. Slamon DJ, Clark GM, Wong SC, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
145. Wright C, Nicholson S, Angus B, et al. Relationship between c-erb-B2 protein expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992; 65: 118-21.
146. Paik S, Hartmann DP, Dickson RB, Lippman ME. Antiestrogen resistance in ER positive breast cancer cells. Breast Cancer Res Treat 1994; 31: 301-7.
147. Cavailles V, Dauvois S, Danielian PS, Parker MG. Interaction of proteins with transcriptionally active estrogen receptors. Proc Natl Acad Sci 1994; 91: 10009-13.
148. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995; 270: 1354-7.
149. Berry M, Metzger D, and Chambon P. Role of the two activating domains of the estrogen receptor in the cell-type and promoter-context dependent agonisticacyivity of the anti-estrogen 4-hydroxytamoxifen: EMBO J 1990; 9: 2811-8.
150. Tzukerman MT, Esty A, Santiso-Mere D, et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions: Mol Endocrinol 1994; 8: 21-30.
151. Webb P, Lopez GN, Uht R, Kushner PJ. Tamoxifen activation of the estrogen receptor/AP-1 pathway; potential origin for the cell-specific estrogen like effects of antiestrogens. Mol Endocrinol 1995; 9: 443-56.
152. Dumont JA, Bitonti AJ, Wallace CD, Baumann RJ, Cashman EA, Cross-Doersen DE. Progression of MCF-7 breast cancer cells to antiestrogen resistant phenotype is accompanied bty elvated levels of AP-i DNA-binding activity. Cell Growth Different 1996; 7: 351-9.
153. Lu B, Johnston SRD, Scott GK, Kushner PJ, Dowsett M, Benz CC. Increased AP-1 DNA binding activity in tamoxifen-resistant human breast tumors. Proc Am Ass Cancer Res 1997; 38: 437 (A2920).
154. Jones CD, Jevnikar MG, Pike AJ. Antiestrogens. 2. Structure-activity studies in a series of 3-aroxyl-2-arylbenzo|b|thiphene derivatives leading to {6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][2-(piperidinyl) ethoxy-phenyl-methanone hydrochloride} (LY156758), a remarkably effective oestrogen antagonist with only minimal intrinsic estrogenicicty. J Med Chem 1984; 27: 1057-66.
155. Loser R, Seibel K, Roos W, Eppenberger U. In vivo and in vitro antiesotrogenic action of 3-hydroxytamoxifen, tamoxifen and 4-hydroxytamoxifen. Eur J Cancer Clin Oncol 1985; 21: 985-90.
156. Black LJ, Jones CD, Falcone JF. Antagonism of estrogen action with a new benzothiopene derived antiestrogen. Life Sci 1983; 32: 1031-6.
157. Wakeling AE, Bowler J. Steroidal pure antiestrogens. J Endocrinol 1987; 112: R7-10.
158. Haarstad H, Gundersen S, Wist E, Raabe N, Mella O, Kvinnsland S. Droloxifene - a new antiestrogen. A phase II study in advanced breast cancer. Acta Oncolog 1992; 31: 425-8.
159. Masamura S, Santner SJ, Heitjan DF, Santen RL. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995; 80: 2918-25.
160. Murray R, Pitt P. Aromatase inhibition with 4-OH-androstenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Treat 1995; 35: 249-53.
161. Dowsett M, Stein RC, Coombes RC. Aromatase inhibition alone or in combination with GnRH agonists for the treatment of pre-menopausal breast cancer patients. J Steroid Biochem 1992; 43: 155-9.
162. Goldhirsch A, Joss RA, Leuenberger U, Cavailli F, Ryssel H-F, Brunner KW. An evaluation of tamoxifen dose escalation in advanced breast cancer. Am J Clin Oncol 1982; 5: 501.
163. Stewart JF, Minton MJ, Rubens RD. Trial of tamoxifen at a dose of 40 mg daily after disease progression during tamoxifen therapy at a dose of 20 mg daily. Cancer Treat Rep 1982; 66: 1445.
164. Swedish Breast Cancer Cooperative Group. Randomised trial of 2 versus 5 years of adjuvant tamoxifen in post-menopausal early-stage breast cancer. J Natl Cancer Inst 1996; 88: 1543-9.
165. Fisher B, Dignam J, Wieand S, et al. Five versus more than five yars of Tamoxifen therapy for Breast Cancer Patients with negative lymph nodes and estrogen-receptor positive tumors. J Natl Cancer Inst 1996; 88: 1529-42.